Indivior PLC (INVVY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in North Chesterfield, VA, United States. Der aktuelle CEO ist Mark Crossley.
INVVY hat IPO-Datum 2015-06-09, 1,000 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $3.01B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing medications for opioid use disorder and related mental health conditions. The company markets several buprenorphine-based prescription drugs, including SUBLOCADE, a subcutaneous injection, and the SUBOXONE and SUBUTEX sublingual formulations, alongside legacy products such as Temgesic and Buprenex. With operations across approximately 40 countries and a pipeline addressing opioid addiction and schizophrenia, Indivior combines established product revenues with research collaborations to advance treatment options in addiction medicine. Incorporated in 2014 and headquartered in North Chesterfield, Virginia, the company serves patients and healthcare providers globally.
